European Case Law Identifier: | ECLI:EP:BA:2016:T158112.20160915 | ||||||||
---|---|---|---|---|---|---|---|---|---|
Date of decision: | 15 September 2016 | ||||||||
Case number: | T 1581/12 | ||||||||
Application number: | 05077865.3 | ||||||||
IPC class: | C12N 15/31 C07K 14/22 C07K 16/12 C12Q 1/68 A61K 39/095 G01N 33/50 |
||||||||
Language of proceedings: | EN | ||||||||
Distribution: | D | ||||||||
Download and more information: |
|
||||||||
Title of application: | Neisseria antigens and compositions | ||||||||
Applicant name: | GlaxoSmithKline Biologicals S.A. | ||||||||
Opponent name: | Wyeth et al. | ||||||||
Board: | 3.3.08 | ||||||||
Headnote: | - | ||||||||
Relevant legal provisions: |
|
||||||||
Keywords: | Main Request - admissibility (yes); Main Request - meets all requirements of the EPC (yes) |
||||||||
Catchwords: |
- |
||||||||
Cited decisions: |
|
||||||||
Citing decisions: |
|
Source: http://www.epo.org/law-practice/case-law-appeals/recent/t121581eu1.html
Date retrieved: 17 May 2021
18 references found.
Click X to load a reference inside the current page, click on the title to open in a new page.EPC Articles
Case Law Book: II Conditions to be met by an Application
XCLR II E 1.6.1 Combination of features pertaining to separate embodiments; application as filed is not a "reservoir"